Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis

References

• About MS. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/index.aspx [Last accessed 6 September 2010]
   Google Scholar
• Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol 1977;34:585-9
   PubMed Web of Science ®Google Scholar
• Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1649-73
   PubMed Web of Science ®Google Scholar
• De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70
   PubMed Web of Science ®Google Scholar
• Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-71
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78. Erratum in: Neurology 2002;59:480
   PubMed Web of Science ®Google Scholar
• Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther 2006;28:445-60
   PubMed Web of Science ®Google Scholar
• Henze T. What is new in symptom management? Int Mult Scler J 2007;14:22-7
   PubMedGoogle Scholar
• Boissy AR, Cohen JA. Multiple sclerosis symptom management. Expert Rev Neurother 2007;7:1213-22
   PubMedGoogle Scholar
• Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med 1992;83:325-37
   PubMedGoogle Scholar
• Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30:233-67
   PubMedGoogle Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-50
   PubMed Web of Science ®Google Scholar
• Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-6
   PubMed Web of Science ®Google Scholar
• Milligan N, Newcombe R, Compston D. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6
   PubMed Web of Science ®Google Scholar
• Patzold T, Schwengelbeck M, Ossege LM, et al. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 2002;105:164-8
   PubMed Web of Science ®Google Scholar
• Humm AM, Z’Graggen WJ, Bühler R, et al. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry 2006;77:345-50
   PubMed Web of Science ®Google Scholar
• Brown TR, Kraft GH. Exercise and rehabilitation for individuals with multiple sclerosis. Phys Med Rehabil Clin N Am 2005;16:513-55
   PubMedGoogle Scholar
• Khan F, Turner-Stokes L, Ng L, et al. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007;2:CD006036
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502
   PubMed Web of Science ®Google Scholar
• Ampyra (dalfampridine) extended release tablets [prescribing information]. Hawthorne, NY, USA: Acorda Therapeutics, Inc., January 2010
   Google Scholar
• Blight AR. Computer simulation of action potentials and afterpotentials in mammalian myelinated axons: the case for a lower resistance myelin sheath. Neuroscience 1985;15:13-31
   PubMed Web of Science ®Google Scholar
• Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982;306:1529-33
   PubMed Web of Science ®Google Scholar
• Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol 2002;59:1377-80
   PubMed Web of Science ®Google Scholar
• Chiu SY. The roles of potassium and calcium channels in physiology and pathophysiology of axons. In: Waxman SG (ed.) Multiple Sclerosis as a Neuronal Disease. Amsterdam: Elsevier Academic Press, 2005
   Google Scholar
• Coetzee WA, Amarillo Y, Chiu J, et al. Molecular diversity of K + channels. Ann N Y Acad Sci 1999;868:233-85
   PubMed Web of Science ®Google Scholar
• Rudy B. Voltage-gated K + channels. In: Kew J, Davies C (eds) Ion Channels, From Structure to Function. Oxford: Oxford University Press, 2010:21-57
   Google Scholar
• Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68
   PubMed Web of Science ®Google Scholar
• Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-59
   PubMed Web of Science ®Google Scholar
• Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-2
   PubMed Web of Science ®Google Scholar
• Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61
   PubMed Web of Science ®Google Scholar
• Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553-62
   PubMed Web of Science ®Google Scholar
• Shi R, Kelly TM, Blight AR. Conduction block in acute and chronic spinal cord injury: different dose–response characteristics for reversal by 4-aminopyridine. Exp Neurol 1997;148:495-501
   PubMed Web of Science ®Google Scholar
• Karimi-Abdolrezaee S, Eftekharpour E, Fehlings MG. Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma. Eur J Neurosci 2004;19:577-89
   PubMed Web of Science ®Google Scholar
• Fehlings MG, Nashmi R. Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Brain Res 1996;736:135-45
   PubMed Web of Science ®Google Scholar
• Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 1978;153:307-18
   PubMed Web of Science ®Google Scholar
• Kim YI, Goldner MM, Sanders DB. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve 1980;3:112-9
   PubMed Web of Science ®Google Scholar
• Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84
   PubMed Web of Science ®Google Scholar
• Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-92
   PubMed Web of Science ®Google Scholar
• Jones RE, Heron JR, Foster DH, et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-62
   PubMed Web of Science ®Google Scholar
• Stefoski D, Davis FA, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-7
   PubMed Web of Science ®Google Scholar
• Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-8
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-9
   PubMed Web of Science ®Google Scholar
• Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21
   PubMed Web of Science ®Google Scholar
• Van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-30
   PubMed Web of Science ®Google Scholar
• Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci 1996;135:1-9
   PubMed Web of Science ®Google Scholar
• Hobart JC, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;23:1027-40
   Google Scholar
• Albrecht H, Wotzel C, Erasmus LP, et al. Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult Scler 2001;7:105-9
   PubMed Web of Science ®Google Scholar
• Report: 2006 Limited FDA Survey of Compounded Drug Products. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm [Last accessed 6 September 2010]
   Google Scholar
• Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006;30:175-7
   PubMed Web of Science ®Google Scholar
• Pickett TA, Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 1996;3:382-5
   Web of Science ®Google Scholar
• Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995;139:2667-9
   PubMedGoogle Scholar
• Spyker DA, Lynch C, Shabanowitz J, et al. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980;16:487-97
   PubMed Web of Science ®Google Scholar
• Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 1994;32:583-7
   PubMed Web of Science ®Google Scholar
• Burton JM, Bell CM, Walker SE, et al. 4-Aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 2008;71:1833-4
   PubMed Web of Science ®Google Scholar
• Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2009;May 12 [Epub ahead of print]
   Google Scholar
• De Cauwer H, De Wolf P, Couvreur F, et al. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 2009;109:40-1
   PubMed Web of Science ®Google Scholar
• Uges DR, Sohn YJ, Greijdanus B, et al. 4-aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93
   PubMed Web of Science ®Google Scholar
• Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;43:379-85
   PubMed Web of Science ®Google Scholar
• Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I–II, open-label trial. Clin Ther 2009;31:2206-14
   PubMed Web of Science ®Google Scholar
• Vollmer T, Blight AR, Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009;31:2215-23
   PubMed Web of Science ®Google Scholar
• Smith W, Swan S, Marbury T, et al. Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9
   PubMed Web of Science ®Google Scholar
• Nilsagard Y, Lundholm C, Gunnarsson L-G, et al. Clinical relevance using timed walk tests and ‘timed up and go’ testing in persons with multiple sclerosis. Physiother Res Int 2007;12:105-14
   PubMedGoogle Scholar
• Hoogervorst EL, Kalkers NF, Cutter GR, et al. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004;10:55-60
   PubMed Web of Science ®Google Scholar
• Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler 2000;6:286-90
   PubMed Web of Science ®Google Scholar
• Kragt JJ, van der Linden FA, Nielsen JM, et al. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594-8
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology 2002;58:1294-6
   PubMed Web of Science ®Google Scholar
• Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31-6
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87
   PubMed Web of Science ®Google Scholar
• Leary SM, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 2003;206:215-16
   PubMed Web of Science ®Google Scholar
• Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing–remitting multiple sclerosis. Eur J Neurol 2011;18:240-5
   PubMed Web of Science ®Google Scholar
• Acorda Therapeutics: Data on File. Integrated Summary of Safety. Fampridine-SR in Patients With Multiple Sclerosis. NDA 22-250, 2009
   Google Scholar
• Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002;8:495-9
   PubMed Web of Science ®Google Scholar
• Koch M, Uyttenboogaart M, Polman S, et al. Seizures in multiple sclerosis. Epilepsia 2008;49:948-53
   PubMed Web of Science ®Google Scholar
• Kelley BJ, Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009;23:805-15
   PubMed Web of Science ®Google Scholar
• Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004;15:475-95
   PubMed Web of Science ®Google Scholar
• March B, Cardi T. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin Investig Drugs 2009;18:1807-15
   PubMed Web of Science ®Google Scholar
• Renganathan M, Sidach S, Blight AR. Effects of 4-aminopyridine on cloned hERG channels expressed in mammalian cells. Arch Drug Info 2009;2:51-7
   PubMedGoogle Scholar
• Thomas G, Klatt B, Blight A. Effect of 4-aminopyridine on action potential parameters in isolated dog Purkinje fibers. Arch Drug Info 2010;3:19-25
   PubMedGoogle Scholar